TG Therapeutics (NASDAQ:TGTX) Releases Earnings Results

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01), Briefing.com reports. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. TG Therapeutics’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.73 EPS.

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $0.25 on Thursday, reaching $27.42. The stock had a trading volume of 254,056 shares, compared to its average volume of 3,635,252. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $4.25 billion, a P/E ratio of -271.70 and a beta of 2.19. TG Therapeutics has a 1-year low of $9.81 and a 1-year high of $27.79. The stock has a fifty day moving average price of $23.65 and a 200-day moving average price of $20.30.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TGTX. B. Riley lifted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright increased their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.